Identification of a vertebrate sister-chromatid separation inhibitor involved in transformation and tumorigenesis

Science

Volumn 285, Issue 5426, 1999, Pages 418-421

  Zou, Hui ^a   McGarry, Thomas J ^a   Bernal, Teresita ^a   Kirschner, Marc W ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL PROTEIN; COMPLEMENTARY DNA; CYCLIN DEPENDENT KINASE; CYCLINE; MUTANT PROTEIN; SECURIN; UNCLASSIFIED DRUG;

ANAPHASE; ANIMAL CELL; ARTICLE; CARCINOGENESIS; CELL TRANSFORMATION; CONTROLLED STUDY; HELA CELL; HUMAN; HUMAN CELL; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN DEGRADATION; SEQUENCE HOMOLOGY; SISTER CHROMATID; VERTEBRATE; XENOPUS;

3T3 CELLS; AMINO ACID SEQUENCE; ANAPHASE; ANIMALS; CDC2 PROTEIN KINASE; CELL CYCLE PROTEINS; CELL TRANSFORMATION, NEOPLASTIC; CHROMATIDS; CONSERVED SEQUENCE; CYCLIN B; ENDOPEPTIDASES; FUNGAL PROTEINS; HELA CELLS; HUMANS; LIGASES; MICE; MITOTIC SPINDLE APPARATUS; MOLECULAR SEQUENCE DATA; MUTAGENESIS, SITE-DIRECTED; NEOPLASM PROTEINS; NEOPLASMS; NUCLEAR PROTEINS; ONCOGENE PROTEINS; ONCOGENES; SACCHAROMYCES CEREVISIAE PROTEINS; SCHIZOSACCHAROMYCES POMBE PROTEINS; UBIQUITIN-PROTEIN LIGASE COMPLEXES; UBIQUITIN-PROTEIN LIGASES; XENOPUS;

ANIMALIA; SACCHAROMYCETALES; SCHIZOSACCHAROMYCES POMBE; VERTEBRATA;

EID: 0033575347     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.285.5426.418     Document Type: Article

References (35)

1. S. Tugendreich, J. Tomkiel, W. Earnshaw, P. Hieter, Cell 81, 261 (1995).
2. R. W. King et al., ibid., p. 279.
3. S. Irniger, S. Piatti, C. Michaelis, K. Nasmyth, ibid., p. 269.
4. S. L. Holloway, M. Glotzer, R. W. King, A. W. Murray, ibid. 73, 1393 (1993).
5. T. Hirano, S. Funahashi, T. Uemura, M. Yanagida, EMBO J. 5, 2973 (1986).
6. A. Yamamoto, V. Guacci, D. Koshland, J. Cell. Biol. 133, 85 (1996).
7. _, ibid., p. 99.
8. O. Cohen-Fix, J. M. Peters, M. W. Kirschner, D. Koshland, Genes Dev. 10, 3081 (1996).
9. H. Funabiki et al., Nature 381, 438 (1996).
10. R. Ciosk et al., Cell 93, 1067 (1998).
11. H. Funabiki, K. Kumada, M. Yanagida, EMBO J. 15, 6617 (1996).
12. A. Toth et al., Genes Dev. 13, 320 (1999).
13. T. Nagase, N. Seki, K. Ishikawa, A. Tanaka, N. Nomura, DNA Res. 3. 17 (1996).
14. 6 fusion. A 269-amino acid recombinant protein was expressed in Escherichia coli according to the protocol provided by the manufacture (Novagen). Recombinant protein was purified up to 90% with Ni-nitrilotriacetic acid (NTA) beads (Qiagen). Full-length hSecurin (or PTTG) was isolated with primers 5′-ATGGCTACTCTGATCTATGTTGATAAGG-3′ and 5′-TTAAATATCTATGTCACAGCAAACAGGTG-3′. The PCR product was then cloned into a modified version of pCS2 for in vitro translation and transfection into mammalian cells. The same fragment was also cloned into a modified pET28a vector to express recombinant protein in E. coli. Protein more than 90% pure was obtained by affinity purification with Ni-NTA beads (Qiagen) followed by Resource Q column chromatography. Rabbit polyclonal antibodies to the 269-amino acid hESP1 fragment and full-length hSecurin (or PTTG) were made by Zymed with purified recombinant proteins as antigen. Crude sera were affinity-purified by passing them through affinity AffiGel-10 (BioRad) columns coupled with corresponding antigens. Antibodies were eluted from the affinity-columns by 100 mM glycine (pH 2.5) followed by 100 mM triethylamine (pH 11.5). Affinity-purified antibody to hESP1 (anti-hESP1) cross-reacts with Myc tag. This antibody does not bind to in vitro-translated hSecurin (24). The anti-cyclin B1 used in this study was a rabbit antibody purchased from Santa Cruz Biotechnology.
15. E. Harlow and D. Lane, Antibodies: A Laboratory Manual (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1988).
16. 2-M (2N), and the percentage for each stage of the cell cyde was calculated.
17. 2, 1 mM EDTA. 1 mM dithiothreitol, insulin (0.1 mg/ml), and 10% glycerol (same below); once in 300 mM KCI and 0.5% NP-40 wash buffer; and once in 500 mM KCl and 0.5% NP-40 wash buffer.
18. R. W. King, K. D. Lustig, P. T. Stukenberg, T. J. McGarry, M. W. Kirschner, Science 277, 973 (1997).
19. T. J. McGarry and M. W. Kirschner, Cell 93. 1043 (1998).
20. K. L. Kroll, A. N. Salic, L. M. Evans, M. W. Kirschner, Development 125, 3247 (1998).
21. A. Dominguez et al., Oncogene 17, 2187 (1998).
22. L. Pei and S. Melmed, Mol. Endocrinol. 11, 433 (1997).
23. X. Zhang et al., ibid. 13, 156 (1999).
24. H. Zou and W. M. Kirschner, unpublished observation.
25. Single-letter abbreviations for the amino acid residues are as follows: A, Ala; C, Cys; D, Asp; E, Glu; F, Phe; G. Gly; H, His; I, Ile; K, Lys; L. Leu; M, Met; N, Asn; P, Pro; Q, Gln; R, Arg; S, Ser; T, Thr; V, Val; W, Trp; and Y, Tyr.
26. R. W. King, M. Glotzer, M. W. Kirschner, Mol. Biol. Cell 7, 1343 (1996).
27. H. Funabiki et al., EMBO J. 16, 5977 (1997).
28. C. E. Shamu and A. W. Murray. J. Cell. Biol. 117, 921 (1992).
29. X. Zhang et al., J. Clin. Endocrinol. Metab. 84, 761 (1999).
30. C. Lengauer, K. W. Kinzler, B. Vogelstein, Nature 396, 643 (1998).
31. J. T. McGrew, L. Goetsch, B. Byers, P. Baum, Mol. Biol. Cell 3, 1443 (1992).
32. S. Uzawa, I. Samejima, T. Hirano, K. Tanaka, M. Yanagida, Cell 62, 913 (1990).
33. Extract prepared from nocodazole-arrested HeLa S3 celts was fractionated on a Resource Q column with a KCl concentration gradient from 100 mM to 1 M in the lysis buffer. Human ESP1 was eluted at about 250 mM KCl. Fractions containing hESP1 were pooled and loaded onto a Superdex 200 column.
34. C. Fang, H. Yu, M, W. Kirschner, Mol. Cell 2, 163 (1998).
35. We thank C. Pfleger and S. Rankin for comments on the manuscript G. Fang, H. Yu, and other members of the Kirschner laboratory for helpful discussion and technical assistance; C. Pfleger and E. Lee for providing modified pCS2 and pET28a vectors; and Q. Zang for mammalian cell transfection. H.Z. is a fellow of The Jane Coffin Childs Memorial Fund for Medical Research. T.J.M. was supported by a Physician Post-doctoral Grant from the Howard Hughes Medical Institute and a Mentored Clinical Scientist Development Award from the National Heart, Lung, and Blood Institute. Supported by grants GM39023 and GM26875 from NIH awarded to M.W.K.